论文部分内容阅读
目的:观察美沙拉嗪联合双歧三联活菌治疗溃疡性结肠炎的临床效果。方法:选择2014年7月至2015年7月茂名市人民医院收治的溃疡性结肠炎患者80例,按照随机抽样法分为观察组和对照组,各40例。对照组患者服用美沙拉嗪治疗,观察组患者则是同时服用美沙拉嗪和双歧三联活菌进行治疗。观察两组患者采取了不同治疗方法以后的治疗效果、产生的不良反应等情况。结果:经过观察,观察组患者的总有效率(92.5%)明显高于对照组(82.5%);观察组患者腹痛、腹泻等临床症状均明显改善,组间比较,差异具有统计学意义(P<0.05)。在不良反应方面,观察组患者出现不良反应率(5%)明显比对照组(22.5%)低,组间比较,差异具有统计学意义(P<0.05)。结论:对溃疡性结肠炎患者同时服用美沙拉嗪和双歧三联活菌进行治疗,可以提高治疗效果,减少患者对药物的不良反应。
Objective: To observe the clinical effect of mesalazine combined with bifidobacterium viable bacteria in the treatment of ulcerative colitis. Methods: 80 patients with ulcerative colitis admitted to Maoming People’s Hospital from July 2014 to July 2015 were randomly divided into observation group and control group, 40 cases in each group. Patients in the control group were treated with mesalazine, while those in the observation group were treated with mesalazine and bifidobacterium viable. Two groups of patients were observed after treatment with different effects, adverse reactions and so on. Results: After observation, the total effective rate (92.5%) in the observation group was significantly higher than that in the control group (82.5%). Clinical symptoms such as abdominal pain and diarrhea in the observation group were significantly improved, and the differences were statistically significant (P <0.05). Adverse reactions, the observation group of patients with adverse reactions (5%) was significantly lower than the control group (22.5%), between groups, the difference was statistically significant (P <0.05). Conclusion: Treating ulcerative colitis with simultaneous treatment of mesalazine and bifidobacterium triple viable bacteria can improve the therapeutic effect and reduce the patients’ adverse reactions to the drugs.